close read more

key Figures

22,500 employees

including 4,900 in France.

98% of Servier brand-name medicines

active ingredients are synthesized in France.

100 million patients

treated each day worldwide with Group medicines.

150 countries

in which the Group’s medicines are distributed

3 major R&D areas

oncology, immune-inflammatory and neurodegenerative diseases,  cardiometabolism (life-cycle management).

27 projects

in clinical development, including 16 new molecular entities (January 2021).

A strong international presence

96% of Group revenue (from brand-name medicines) generated outside France.

16 chemical and pharmaceutical production sites

15 International Centers for Therapeutic Research

and 4 research institutes (2 in France, 1 in Denmark and 1 in Hungary).

€4.7 billion euros in revenue

comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.

23% of revenue from brand-name medicines invested in R&D

in 2019/2020

31st largest pharmaceutical Group worldwide

and 2nd largest pharmaceutical Group in France[1].

A leader position in cardiology in France

5th leading pharmaceutical Group worldwide[1].

Participation reached 36% of the trade balance surplus in France

in pharmaceuticals and fine chemicals (brand-name medicines), amounting to €1.6 billion.

Key figures as of September 30th, 2020

 

[1] Source: IQVA, Analytics Link – September 2020